Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Actemra claims advantage over Humira in rheumatoid arthritis

This article was originally published in Scrip

Executive Summary

Roche is claiming victory for Actemra (tocilizumab) over Abbott's rival rheumatoid arthritis drug Humira (adalimumab) in the first head-to-head study between the two products in a monotherapy setting.



Related Companies